A5102766795- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Cytokine Signaling Pathways and Interactions
- Chronic Myeloid Leukemia Treatments
- Liver Disease Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Cancer survivorship and care
- Palliative Care and End-of-Life Issues
- Gastric Cancer Management and Outcomes
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Esophageal and GI Pathology
- Immunodeficiency and Autoimmune Disorders
- Immunotherapy and Immune Responses
- Metabolism and Genetic Disorders
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Immune Cell Function and Interaction
- Retinoids in leukemia and cellular processes
- Cancer Treatment and Pharmacology
Cytel (United States)
2025
Center for Drug Evaluation and Research
2021-2024
United States Food and Drug Administration
2019-2024
Kaleida Health
2014
McMaster University
2013
Columbia University
2013
Leukemia Research Foundation
2007-2010
Duke Medical Center
2008-2010
Dartmouth–Hitchcock Medical Center
2010
University of Iowa
2010
To evaluate the safety and efficacy of fludarabine plus rituximab in treatment-naive or relapsed patients with low-grade and/or follicular non-Hodgkin's lymphoma.This was an open-label, single-arm, single-center phase II study enrolling 40 patients. During first week study, received two infusions 375 mg/m2 administered 4 days apart. Seventy-two hours after second infusion rituximab, six cycles chemotherapy (25 mg/m2/d for 5 on a 28-day cycle). Single were 72 before second, fourth, sixth...
The use of flow cytometry to diagnose hematological malignancies has become routine due its ability often differentiate between morphologically similar diseases based on antigens expressed the surface malignant cells. In an attempt expand utility in study B-cell we have used most reliable quantitative methodology, QIFI (quantitative indirect immunofluorescence assay), expression CD5, CD10, CD11c, CD19, CD20, CD22, CD23, and CD79b 384 cases several common B-lineage malignancies, including:...
Abstract Objective : Improving diet and exercise can reduce survivors' risk of cancer‐related fatigue, poor physical functioning, potential recurrence. A cancer diagnosis represent a ‘teachable moment’, leading survivors to make positive changes in behaviors; however, little is known about how often this occurs or factors that enhance limit ability these changes. This cross‐sectional descriptive study investigated both the prevalence clustering self‐reported related ongoing symptoms, social...
In the United States, 5% of population is responsible for nearly half all health care expenditures, with a large concentration spending driven by individuals expensive chronic conditions in their last year life. Outpatient palliative under Medicare Hospice Benefit excludes proportion chronically ill and there widespread recognition that innovative strategies must be developed to meet needs seriously while reducing costs.This study aimed evaluate impact home-based program, implemented through...
To determine if alemtuzumab consolidation improves response rate and progression-free survival (PFS) after induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic leukemia.Patients (n = 102) received fludarabine 25 mg/m(2) intravenously days 1 to 5 rituximab 50 day 1, 325 3, 375 of cycle then cycles 2 6; plus (FR) administration was repeated every 28 for six cycles. Three months completion FR, stable disease or better subcutaneous 3 mg 10 30 three...
In the nucleos(t)ide analog (NA)-control arm of REEF-2 study (NCT04129554), virologic relapse (confirmed increase in HBV DNA >2000 IU/mL) and biochemical flare (ALT increases ≥3× upper limit normal) were frequently observed after stopping NA treatment. We characterized posttreatment relapses flares assessed their association with end-of-treatment (EOT) serum markers. REEF-2, a randomized-controlled study, virologically suppressed HBeAg-negative patients stopped treatment at week 48, followed...
Abstract Purpose: Arsenic trioxide decreases proliferation of acute myeloid leukemia (AML) cells, but its precise mechanism action is unknown. Experimental Design: We studied the effect arsenic on patient samples and AML cell line HEL, which, like leukemic blasts from 50% cases, has constitutively activated signal transducer activator transcription (STAT) proteins. Results: induced mitotic arrest starting at 24 hours significant death 48 hours. These events were preceded by an dose-dependent...
Abstract BACKGROUND: Little is known about cancer surveillance (mammography, clinical breast examination, and pelvic examination) behaviors in long‐term (9‐16 years) survivors. This report describes the relation of these to demographic characteristics, psychological symptoms, body satisfaction, social support. METHODS: Survivors who had participated Cancer Leukemia Group B treatment Trial 8541 completed a survey that included questions on well being, RESULTS: The participation rate was 78%...
Abstract BACKGROUND: The Survivor's Health and Reaction (SHARE) study examined health‐related quality of life (HRQL) in breast cancer patients who had participated Cancer Leukemia Group B Trial 8541 from 1985 to 1991. METHODS: In total, 245 survivors (78% eligible patients) were 9.4 16.5 years postdiagnosis (mean, 12.5 postdiagnosis) completed HRQL surveys relating 5 domains. Analyses domains according 3 different chemotherapy dose levels that administered the original treatment trial:...
Trefoil peptides (TFF-1, 2, 3) are a family of protease-resistant regulatory factors that play role in mucosal restitution, angiogenesis, apoptosis, and tumor progression. Intestinal trefoil peptide (TFF-3) expression has been demonstrated benign hepatobiliary diseases, but there limited data regarding its HCC.Thirty consecutive cases HCC from 1998 to 2003 were studied. Immunohistochemistry was performed on formalin-fixed paraffin-embedded blocks using polyclonal antibody TFF-3. TFF-3...
The CALGB studied the feasibility and effectiveness of adding oblimersen (G3139; Genasense) to imatinib mesylate (IM) in imatinib-resistant chronic phase myeloid leukemia (CML) patients. We hypothesised that IM resistant CML cells are no longer being driven proliferate by Bcr/Abl activity alone. Instead, anti-apoptotic protein Bcl-2 would regulate one pathways controlling growth and/or viability. Thus, blocking both simultaneously result hematologic cytogenetic improvement. Oblimersen was...